Reactive oxygen : A novel antimicrobial mechanism for targeting biofilm-associated infection
Copyright © 2017 International Society for Chemotherapy of Infection and Cancer. All rights reserved..
Reactive oxygen species (ROS) is a novel therapeutic strategy for topical or local application to wounds, mucosa or internal structures where there may be heavy bacterial bioburden with biofilm and chronic inflammation. Bacterial biofilms are a significant problem in clinical settings owing to their increased tolerance towards conventionally prescribed antibiotics and their propensity for selection of further antibacterial resistance. There is therefore a pressing need for the development of alternative therapeutic strategies that can improve antibiotic efficacy towards biofilms. ROS has been successful in treating chronic wounds and in clearing multidrug-resistant organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and carbapenemase-producing isolates from wounds and vascular line sites. There is significant antifungal activity of ROS against planktonic and biofilm forms. Nebulised ROS has been evaluated in limited subjects to assess reductions in bioburden in chronically colonised respiratory tracts. The antibiofilm activity of ROS could have great implications for the treatment of a variety of persistent respiratory conditions. Use of ROS on internal prosthetic devices shows promise. A variety of novel delivery mechanisms are being developed to apply ROS activity to different anatomical sites.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Journal of global antimicrobial resistance - 8(2017) vom: 15. März, Seite 186-191 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dryden, Matthew S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Infective Agents, Local |
|---|
| Anmerkungen: |
Date Completed 17.12.2018 Date Revised 17.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jgar.2016.12.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM269078754 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM269078754 | ||
| 003 | DE-627 | ||
| 005 | 20231224223853.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jgar.2016.12.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0896.xml |
| 035 | |a (DE-627)NLM269078754 | ||
| 035 | |a (NLM)28213334 | ||
| 035 | |a (PII)S2213-7165(17)30017-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dryden, Matthew S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reactive oxygen |b A novel antimicrobial mechanism for targeting biofilm-associated infection |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.12.2018 | ||
| 500 | |a Date Revised 17.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 International Society for Chemotherapy of Infection and Cancer. All rights reserved. | ||
| 520 | |a Reactive oxygen species (ROS) is a novel therapeutic strategy for topical or local application to wounds, mucosa or internal structures where there may be heavy bacterial bioburden with biofilm and chronic inflammation. Bacterial biofilms are a significant problem in clinical settings owing to their increased tolerance towards conventionally prescribed antibiotics and their propensity for selection of further antibacterial resistance. There is therefore a pressing need for the development of alternative therapeutic strategies that can improve antibiotic efficacy towards biofilms. ROS has been successful in treating chronic wounds and in clearing multidrug-resistant organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and carbapenemase-producing isolates from wounds and vascular line sites. There is significant antifungal activity of ROS against planktonic and biofilm forms. Nebulised ROS has been evaluated in limited subjects to assess reductions in bioburden in chronically colonised respiratory tracts. The antibiofilm activity of ROS could have great implications for the treatment of a variety of persistent respiratory conditions. Use of ROS on internal prosthetic devices shows promise. A variety of novel delivery mechanisms are being developed to apply ROS activity to different anatomical sites | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Biofilm | |
| 650 | 4 | |a Chronic wounds | |
| 650 | 4 | |a Cystic fibrosis | |
| 650 | 4 | |a Prosthetic device infection | |
| 650 | 4 | |a Reactive oxygen species | |
| 650 | 7 | |a Anti-Infective Agents, Local |2 NLM | |
| 650 | 7 | |a Reactive Oxygen Species |2 NLM | |
| 700 | 1 | |a Cooke, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Salib, Rami J |e verfasserin |4 aut | |
| 700 | 1 | |a Holding, Rebecca E |e verfasserin |4 aut | |
| 700 | 1 | |a Biggs, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Salamat, Ali A |e verfasserin |4 aut | |
| 700 | 1 | |a Allan, Raymond N |e verfasserin |4 aut | |
| 700 | 1 | |a Newby, Rachel S |e verfasserin |4 aut | |
| 700 | 1 | |a Halstead, Fenella |e verfasserin |4 aut | |
| 700 | 1 | |a Oppenheim, Beryl |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Cox, Sophie C |e verfasserin |4 aut | |
| 700 | 1 | |a Grover, Liam M |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Hindi, Zain |e verfasserin |4 aut | |
| 700 | 1 | |a Novak-Frazer, Lilyann |e verfasserin |4 aut | |
| 700 | 1 | |a Richardson, Malcolm D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of global antimicrobial resistance |d 2013 |g 8(2017) vom: 15. März, Seite 186-191 |w (DE-627)NLM237523876 |x 2213-7173 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2017 |g day:15 |g month:03 |g pages:186-191 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jgar.2016.12.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2017 |b 15 |c 03 |h 186-191 | ||